Dr Paul Eleftheriou

Principal at Nous Group

Paul is a Principal at the Nous Group, an International Management Consultancy. Originally from a medical background, Paul spent just over a decade in senior leadership roles in healthcare, most recently as the Chief Medical Officer of Western Health. He has worked across the public and private healthcare sectors, including deep experience in health education, research and innovation.

A/Prof Daryl Cheng

Consultant Paediatrician, Department of General Medicine at The Royal Children's Hospital

A/Professor Daryl Cheng lives and practices at the intersection of health, illness, technology and wellbeing. Bringing together his passion for holistic health, informatics, systems thinking and social enterprise, he works across a variety of environments and initiatives to improve life for children and their families.

Rosie Stramandolini

Special Counsel Patent & Trade Mark Attorney(AU,NZ) at Pearce IP

With over 30 years of IP career experience, Rosie strategically manages and oversees complex matters for local and global matters for clients in the life sciences industries including the pharmaceutical, biopharmaceutical, biotech and med-tech industries. Her experience extends to patent drafting, prosecution, opposition, management of clients’ IP portfolios including licensed IP rights, due diligence analyses, and commercialisation of IP rights. Rosie also has considerable experience in providing patent infringement opinions and freedom to operate analyses.

Senior Investment Manager at IP Group

Alisa is Senior Investment Manager at IP Group Australia. Her main role is to identify, develop and pitch new opportunities for investment, and then actively manage portfolio companies as Board Director or Observer. Prior to her return to Australia in 2017, Alisa spent eight years in Oxford, UK, where she worked in life sciences strategy and M&A consulting at PharmaVentures, and in the Corporate Development team at Circassia, where she worked on the company’s £275M fundraise in 2015. Alisa holds a PhD in Biomedical Engineering from the University of Oxford, and a Bachelor of Engineering / Bachelor of Life Sciences from Flinders University.

Michelle He

Investment Manager at Tin Alley Ventures

Michelle is an investment manager at Tin Alley Ventures, focusing on life sciences investments. Michelle started her career in the investment banking division at Goldman Sachs and has also worked in the investment team at BGH Capital and in the Strategy & Operations team at FrankieOne. She holds a Bachelor of Science, majoring in Neuroscience, from the University of Melbourne.

Bob Soh

Senior Investment Manager at Brandon Capital

Prior to joining Brandon Capital, Bob worked at Nucleus Network, Australia’s largest clinical trials unit. He was an investigator in over 100 early phase clinical trials, including as PI. He was heavily involved in various aspects of the business, including overseeing its clinical operations, business development and expanding Nucleus Network’s trial capabilities. During his time at Nucleus Network, he was concurrently appointed as the acting CEO for Cardiora, a Brandon Capital investee company developing therapies for heart failure. He successfully led Cardiora through phase 2 clinical trials, and successfully led the Company’s FDA regulatory and IP strategy. The program was subsequently licensed to a specialty pharmaceutical company.

Andrew Venables 

CEO of Loxegen

Andrew is the CEO of Loxegen, a biotech company focusing on lung gene therapy targeting cystic fibrosis using a nanoparticle delivery system. He has 25+ years experience in law, finance and economics, including 10 years as a Partner of a leading corporate law firm. Andrew is also experienced in financing gene therapy strategies for treating cystic fibrosis.